BXP, Inc.

BXP reported Q2 2026 FFO of $1.78 per share, which exceeded both guidance and consensus by $0.08 per share. Revenue outperformed expectations by $0.04 per share, driven by $0.03 per share of higher rental revenue and $0.01 per share of higher service income. Management also cited $0.04 per share of benefit from lower operating expenses, partly offset later in the year by deferred maintenance and other costs. Occupancy increased to 88.4% at June 30, 2026, versus 87.4% in Q1 and 86.7% at year-end 2025. For full-year 2026, BXP raised FFO guidance to $6.99-$7.05 per share, up $0.05 at the midpoint, and increased its expected average occupancy to 88.9%; management now expects year-end occupancy closer to 90%. The company also raised its same-property NOI growth assumption to 1.8%-2.6% and increased development NOI assumptions by $0.03 per share, partially offset by about $0.05 per share of NOI reduction from asset sales.

Owen Thomas framed the quarter as strong operationally and financially, emphasizing that BXP is executing on its three-part business plan: lease space and lift occupancy, monetize non-core assets, and grow FFO through selective development. He highlighted AI as a meaningful tailwind for premier workplaces, arguing that gateway CBD assets are best positioned to benefit from AI-driven demand and tighter labor markets. His tone was confident and upbeat, with repeated references to being ahead of schedule on occupancy and asset sales and to a portfolio that is increasingly concentrated in premier, AI-resilient markets.

Mike LaBelle focused on the financial bridge behind the quarter and the guidance increase. He said nearly all the FFO beat came from portfolio NOI, with revenue up $0.04 per share and operating expenses contributing another $0.04 per share of outperformance, while some of the expense benefit should normalize later in the year. He also detailed the $1.2 billion five-year construction loan for 343 Madison at SOFR plus 250 bps, stepping down to 225 bps at milestones, and noted the company may use cash to reduce that financing by up to $300 million. On capital allocation, he said the accelerated asset-sale pace is slightly more dilutive in 2026, with foregone NOI reducing FFO by about $0.02 per share versus prior assumptions, but the proceeds support lower leverage and future flexibility.

Analysts pressed on how asset sales would affect 2027, with management saying 2026 dilution is now closer to $0.11 per share versus an earlier $0.06-$0.09 range, and that 2027 will likely be lighter because many sales will have closed by year-end 2026. They also asked whether excess sale proceeds could be used for buybacks; management said that option is on the table, alongside new developments, as leverage moves toward the low-7x range. Other questions focused on stabilized occupancy, with Doug Linde saying the portfolio could ultimately top out around 94%-95%, though BXP is still sticking to 91% by end-2027 for now. Analysts also asked about AI demand and whether it could echo the prior life science cycle; management said most leasing benefits are indirect, coming from market tightening and displacement, though they are also leasing directly to AI companies with credit protections.